A global chromoblastomycosis strategy and development of the global chromoblastomycosis working group.


Journal

PLoS neglected tropical diseases
ISSN: 1935-2735
Titre abrégé: PLoS Negl Trop Dis
Pays: United States
ID NLM: 101291488

Informations de publication

Date de publication:
Oct 2024
Historique:
medline: 15 10 2024
pubmed: 15 10 2024
entrez: 15 10 2024
Statut: epublish

Résumé

Chromoblastomycosis, an implantation mycosis, is a neglected tropical disease that causes decreased quality of life, stigma, and disability. The global burden of disease is unknown and data on disease epidemiology and outcomes are severely limited by a lack of access to needed diagnostic tools and therapeutics. The World Health Organization outlined targets for chromoblastomycosis in the Road Map for Neglected Tropical Diseases 2021-2030, but little progress has been made in initiating and implementing an effective control program globally. This lack of guiding policy and progress led to the recent formation of a Global Chromoblastomycosis Working Group which has developed a global chromoblastomycosis strategy. We describe this strategy, which outlines specific steps needed to improve technical progress, strategy and service delivery, and enablers. Clinicians, researchers, public and government officials, patients, and policy makers can align their time, expertise, and resources to improve the lives of communities affected by chromoblastomycosis through this strategy.

Identifiants

pubmed: 39405322
doi: 10.1371/journal.pntd.0012562
pii: PNTD-D-24-01135
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0012562

Informations de copyright

Copyright: This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Auteurs

Dallas J Smith (DJ)

Mycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.

Flávio Queiroz-Telles (F)

Department of Public Health, Federal University of Paraná, Curitiba, Brazil.

Fahafahantsoa Rapelanoro Rabenja (FR)

LARTIC Laboratory, Faculty of Medicine, University of Antananarivo, Antananarivo, Madagascar.

Roderick Hay (R)

King's College London, London, United Kingdom.

Alexandro Bonifaz (A)

Servicio de Dermatología, Hospital General de México "Dr. Eduardo Liceaga", Mexico City, Mexico.

Marlous L Grijsen (ML)

Oxford University Clinical Research Unit Indonesia, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia.
Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, United Kingdom.

Romain Blaizot (R)

Department of Dermatology, Andrée Rosemon Hospital, 97306 Cayenne, French Guiana.
Tropical Biome and Immunophysiopathology (TBIP), Université de Lille, CNRS, Inserm, Institut Pasteur de Lille, U1019-UMR9017-CIIL-Centre d'Infection et d'Immunité de Lille, Centre Hospitalier de Cayenne, Université de Guyane, Cayenne, French Guiana.

Fernando Messina (F)

Unidad Micología, Hospital de Enfermedades Infecciosas Francisco Javier Muñiz, Buenos Aires, Argentina, Hospital de Enfermedades Infecciosas Francisco Javier Muñiz, Buenos Aires, Argentina.

Yinggai Song (Y)

Department of Dermatology, Peking University First Hospital, Peking University, Beijing China.

Shawn R Lockhart (SR)

Mycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.

Alexander Jordan (A)

Mycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.

Alyson M Cavanaugh (AM)

Mycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.

Anastasia P Litvintseva (AP)

Mycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.

Tom Chiller (T)

Mycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.

Marco Schito (M)

Critical Path Institute, Tucson, Arizona, United States of America.

Sybren de Hoog (S)

Radboudumc/CWZ Center of Expertise in Mycology, Nijmegen, the Netherlands.

Vania Aparecida Vicente (VA)

Basic Pathology Department, Federal University of Parana, Curitiba, Brazil.

Muriel Cornet (M)

Université Grenoble Alpes, Grenoble, France.

Daniel Argaw Dagne (DA)

Department of Control of Neglected Tropical Diseases, WHO, Geneva, Switzerland.

Lala S Ramarozatovo (LS)

Hôpital Universitaire Joseph Raseta Befelatanana, Antananarivo, Madagascar.
Centre Hospitalier Universitaire de Befelatanana, Antananarivo, Madagascar.

Conceição de Maria Pedrozo E Silva de Azevedo (CMPES)

Department of Medicine, Federal University of Maranhão, São Luís, Maranhão, Brazil.
Post-graduation Program of Health Science, Federal University of Maranhão, São Luís, Maranhão, Brazil.

Daniel Wagner C L Santos (DWCL)

Department of Infectious Diseases and Infection Control, Universidade Federal do Maranhão, Maranhão, Brazil.
Instituto D´Or de Pesquisa e Ensino, IDOR, Brazil.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH